Participate in a Groundbreaking Non-Invasive Imaging Trial
A diagnosis of HR-/HER2+ breast cancer can be scary, and identifying the right course of action is overwhelming. That’s why research is so important!
BAMF Health is at the forefront of research. We are launching a non-invasive imaging clinical trial for those with HR-/HER2+ metastatic breast cancer. This trial aims to understand the prevalence of a specific biomarker in this subset of breast cancer. We invite you to apply.
Women with breast cancer deserve more options—help us get there faster.
Eligibility and Benefits
Eligibility Criteria
- At least 18 years old
- Diagnosed with HR-/HER2+ metastatic breast cancer
- At least one measurable tumor lesion on conventional imaging
- Women of childbearing potential must have a negative pregnancy test
Benefits to Participating
- Receive an advanced PET scan at BAMF Health
- Images will be sent to your doctor
- $500 stipend provided
- The opportunity to advance options for women diagnosed with breast cancer
Let's Advance Research Together!
BAMF Health Clinical Trial Updates
BAMF Health Doses First Patient in Promising New Prostate Cancer Alpha Radioligand Therapy Clinical Trial
BAMF Health dosed the first patient enrolled in a Phase 1 prostate cancer therapy clinical trial sponsored by ARTBIO.
November 25, 2025
It Takes Courage. God Gave Me Courage.
With a zest and appreciation for life, at 77 years old, Barbara considered herself the picture of perfect health. But that changed in June of 2025 when she was diagnosed with metastatic HR-/HER2+ breast cancer.
October 2, 2025
East River Medical Imaging Selected as First BAMF RadioNexus Site in the New York City Area
Partnership brings new cancer trial and treatments to patients in New York City and Westchester.
September 9, 2025